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INTRODUCTION
INTRODUCTION
Recentlyin the field  of pharmaceutical  technology great  efforts  are being directed
towards the refabrication of existing drug molecules in a fashion, capable of solving problem
related to poor water solubility, poor bioavailability, dosing problem, stability, toxicity, etc.
This trend of working has led to development of new drug delivery systems.
Even today, conventional drug delivery systems are primary pharmaceutical products
commonly seen in prescriptions and ‘over the counter’ market place. They provide prompt
release of the drug but in order to achieve as well as maintain drug concentration within
therapeuticallyachieved  range,itisoften  necessary  to  administer  it  several  times  a  day.
Conventional  drug  therapy  results  in  significant  fluctuations  of  drug  concentration  in
systemic circulation causing either lethal effect
or no therapeutic action.1
Basic goal of drug therapy is to provide therapeutic amount of drug to proper site in
body to  promptly achieve  and  then  maintain  desired  drug  concentration.  This  idealized
objective points to two aspects most important to the drug delivery, namely spatial placement
and temporal delivery of drug. Spatial placement relates to targeting a drug to specific organ
or tissue while temporal delivery refers to controlling rate of drug delivery to that specific
organ or tissue.2
Despite tremendousadvancement in drug delivery, oral route remains preferred route
for administration.3   Oral controlled release dosage forms have been developed over past
three  decades.  These  drug  delivery  system  have  a  great  potential  of  solving  problems
associated with conventional multiple dosing system like strict adherence to timely dosing,
flip flop plasma concentration, associated side effects due to  systemic  accumulation  of
drug.  Thus,  there  are  numerous  advantages  such  asimproved efficacy, reduced toxicity,
improved patient compliance and convenience, reduction in health care cost, etc.4  However,
this approach is bedilled with several physiological difficulties such as inability to restrain
and locate controlled drug delivery system within the desired region of GIT, due to variable
gastric  emptying  and  motility.  Furthermore  the  relative  brief  gastric  emptying  time  in
humans which normally averages 2-3 hrs through major absorption zone i.e. stomach and
upper  part  of  intestine  can  result  in  incomplete  drug release  from drug delivery system
leading to low bioavailability and thus reduced efficacy of administered dose.5
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Efforts   to   improve   oral   drug   bioavailability   have   grown   in   parallel
withpharmaceutical  industry.  As  the  number  and  chemical  diversity  of  drugs  has
increased, new strategies are required to develop orally active therapeutics. The past  two
decades  have  been  characterised  by  an  increased  understanding  of  causes  of  low
bioavailability  and great  deal  of  innovation  in  oral  delivery technologies,  marked  by an
unprecedented growth of drug delivery industry.6
It is evident from the recent scientific and patent literature that an increasedinterest in
novel dosage forms that are retained in stomach for prolonged and predictable period of time
exists today in academic and industrial research groups. One of the most feasible approaches
for achieving a prolonged and predictable drug delivery profile in GIT is to control gastric
residence time.7
Control  of  placement  of  drug  delivery  system  in  specific  region  of  GIT
offersadvantage for variety of important drugs characterized by narrow absorption window in
GIT  or  drugs  with  stability  problem.  These  considerations  have  led  to development of
unique oral controlled release dosage form with gastro retentive properties i.e. dosage form
could be retained in the stomach for several hours andrelease the drug there in a controlled
and prolonged manner, so that drug could be supplied continuously to its absorption site in
the upper GIT.5
To comprehend the considerations taken in design of gastro retentive dosage forms
and to evaluate their performance, the relevant anatomy and physiology of GIT must be fully
understood.8
The GIT is essentially a tube about 9 m long that runs through middle ofbody from
mouth to anus and include throat(pharynx), oesophagus, stomach, small intestine(consisting
of duodenum, jejunum and ileum) and large intestine(consisting of cecum, appendix, colon
and retum). In the living person it is shorter because the muscles along walls of GIT organs
are in state of tone (sustained contraction). Wavelike contractions of smooth muscle in wall
of GIT propel the food along the tract from oesophagus to anus.9
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Stomach: An overview
The  stomach  is  J  shaped  enlargement  of  GIT  directly  inferior  to  diaphragm  in
epigastric, umbilical and left hypochondriac regions of abdomen. It connects oesophagus  to
duodenum,  first  part  of  small  intestine  and  provides  a  barrier  to delivery of drugs to
small intestine. Its size varies according to amount of distention: up to 1500 ml following a
meal; after food has emptied, a collapsed state is obtained with resting volume of only 25-50
ml.
Anatomy of stomach
The stomach has four regions:
• Cardia
.
• Fundus.
• Body
• Pylorus.
Fig No.1: Anatomy of Stomach
Cardia surrounds superior opening of stomach. The rounded portion superior to and
to the left of cardia is  fundus. Inferior to fundus is large central portion of stomach called
body. The region of stomach that connects to duodenum, is pylorus. It has two parts pyloric
antrum, which connects to the body of stomach and pyloric canal which leads to duodenum.
The pylorus communicates with duodenum of small  intestine via sphincter called pyloric
spincter.
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The  main  function  of  the  fundus  and  body is  storage,  whereas  that  of  cardia  is
mixingor grinding. The fundus adjusts the increased volume during eating by relaxation of
the fundus muscle fibres. The fundus also exerts a steady pressure on the gastric contents
pressing them towards the distal region. The pyloric sphincter has diameter of 12.867 mm in
humans and act as sieve as well as mechanical stricture to passage of large particles. Antrum
does grinding.
Histology of stomach
The stomach wall is composed of the four basic layers. Simple columnar epithelial
cells line the entire mucosal surface of the stomach. Epithelial cells extend down into the
lamina propria, where they form columns of secretary cells calledgastric glands. The gastric
glands contain three types of exocrine gland cells that secrete their products into the stomach
lumen.
• Mucous neck cells.
• Chief cell.
• Parietal cells.
The  chief  cells  secrete  pepsinogen  and  gastric  lipase.  Parietal  cells  produce
hydrochloric acid and intrinsic factor.  Both mucosal  surface cells and mucous neck cells
secrete  mucus  and  bicarbonate.  They  protect  the  stomach  from  adverse  effects  of
hydrochloric acid as mucosa has a lubricating effect, it allow chyme to move freely through
the digestive system.
Functions of stomach
The  stomach  carries  out  three  major  functions.  It  stores  food,  digests  food  and
delivers food to the small intestine at a rate that the small intestine can handle.
• Mixes saliva, food, and gastric juice to form chyme.
• It acts as a reservoir for holding food before release into the small intestine.
• Secretes gastric juice, which contains hydrochloric acid, pepsin, intrinsic factor and 
gastric lipase.
• Secrete gastrin into the blood.
Physiology of stomach
Various factors  like the absorption ability,  presystemic clearance,  gastric  motility,
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gastrointestinal transit time and gastrointestinal emptying time will have an influence on the
bioavailability of drug from the dosage form.
Absorption ability
The absorption capability of various segments of gastrointestinal tract differs from
each  other  i.e.  most  of  the  absorption  takes  place  in  small  intestine  and  lesserextent  in
stomach and colon.  Unless  drugs  are  absorbed  equally  in  small  intestine  and colon,  the
duration for most of the drugs is 3-8 hours. This is the major limiting factor for sustained
release and controlled release drug delivery systems.
Presystemic clearance
Even  if  drugs  are  absorbed  equally  well  throughout  the  gastrointestinal  tract,
bioavailability is significantly reduced by the site-specific changes in presystemic clearance.
Degradation of the drug is also carried out by hydrolysis in the stomach, enzymatic digestion
and  metabolism in  the  brush  border  of  the  gut  wall  and  by  the  microorganisms.  Such
degradation may lead to high variation in the plasma drug concentration and poor absorption
of drug into systemic circulation.
Gastric emptying
The total transit time of foods and dosage forms in human from stomach to ileocecal
junction is  approximately 3 to 6 hr  and 6 to 10 hr in fasted and fed states respectively.
Process of gastric emptying occurs in both during fed and fasted states. However, the pattern
of motility differs markedly in the two states.
In fasted state, it is characterized by interdigestive cycle both through stomach and
small  intestine,  every 2-3  hrs.  This  activity  is  called  interdigestive  myoelectric  cycle  or
migrating myoelectric complex. Each cycle lasts 90-120 minutes and is composed of four
phases12.
Phase  I  lasts  40-60  minutes,  in  which  contraction are  at  minimum, there is  little  or  no
movement of liquid or solids through intestine.
Phase  II  with  a  length  of  20-40  minutes  has  intermediate  amplitude contraction and
involves bile secretions.
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Phase III is also termed ‘housekeeper waves’ and extends for 10-20 minutes. It is initiated in
thestomach in most cases or in the duodenum, with very high amplitude contraction, with a
frequency of 4-5 Hz per minute and maximal pyloric opening, characterizing this phase,
which enables efficient evacuation of stomach contents. The segregation of liquid and solid
occurs, liquid tend to migrate during phase II and solid during phase III.
Phase IV is brief transitional phase that occurs between phase II and phase III. Phase IV has
a length of less than 5 minutes and connects the maximal amplitude contractions to the basal
phase.  In  the  fed  state,  the  gastric  emptying  rate  is  slowed  since  the  onset  of  MMC is
delayed. In other words, feeding results in a lag time prior to the onset of gastric emptying.
The digestive or fed state is  observed in response to meal ingestion. It  resembles
fasting phase II and is not cyclical, but continuous, provided that the food remains in the
stomach. It is thought that the sieving efficiency (i.e. ability of stomach to grind food into
smaller size) of the stomach is enhanced by fed pattern or by the presence of food. Patterns
of contractions in the stomach occur such that solid food is reduced to particles of less than 1
mm diameter that are emptied through pylorus as
suspension.
Fig No. 2: Schematic representation of interdigestive motility pattern
Table No. 1: Salient Features Of Upper Gastrointestinal Tract
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Section Length(m)
Transit
time (h) pH
Microbial
count
Absorbing
surface
area (m2)
Absorption
pathway
Stomach 0.2 Variable 1-4 <103 0.1 P, C, A
Small
Intestine
6-10 3 ± 1 5-7.5 103 – 1010 120-200 P,  C,  A,  F, 
I, E, CM
P –  Passive diffusion                            C – Aqueous channel transport
A –  Active transport                             F – Facilitated transport
I –   Ion-pair transport                          E –  Entero-or pinocytosis
CM – Carrier mediated transport
Since  most  of  the  drugs  are  absorbed  from the  upper  part  of  intestine,  the  total
effective time for the drug absorption is 3-8 hours. So one has to take most of the drugs 3-6
times a day.
Regulation of gastric secretion
Both neural and hormonal mechanisms control the secretion of gastric juice and the
contraction of smooth muscles in the stomach wall. Events in gastric secretion occur in three
overlapping phases: cephalic phase, gastric phase and intestinal phase.
1. Cephalic phase
The cephalic phase refers to the influence of the brain on secretion. Even before food
enters the stomach, the sight, taste or thought of food initiate this phase,  the secretion is
brought about through stimulation of the nerve. This leads to presence of acid and pepsin in
the stomach even before food enters the stomach.
2. Gastric phase
The  gastric  phase  of  secretions  is  brought  about  by the  presence  of  food  in  the
stomach. It is controlled by the hormone gastrin, which is produced in the mucosa of
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pyloric region of stomach. Gastrin is released in response to stretching of the antrum caused
by  the  presence  of  food  in  this  region  or  in  response  to  specific  substance  in  food;
particularly proteins, alcohol and coffee are also potent stimulants of gastrin release. Once
released,  the gastrin is  transported through the blood to  stomach where it  stimulates  the
secretion of hydrochloric acid and pepsinogen.
3.   Intestinal phase
The intestinal phase of acid secretion refers to the influence of the small intestine on
gastric secretion. If the material present in the duodenum of the small intestine is too acidic,
a hormone is released by the intestinal mucosa. This hormone is carried by blood to the body
of the stomach where it inhibits further acid secretion. This serves as a protective device for
the small intestine, which is not well protected against acid as the stomach. The total volume
of gastric secretion in response to all the stimuli mentioned above is approximately 2-3 liters
per day.
Factors Affecting Gastric Retention
1. Density:  GRT is  a  function  of  dosage  form  buoyancy  that  is  dependent  on  the
density.  Density  of  the  dosage  form  should  be  less  than  the  gastric  contents
(1.004gm/ml).
2. Size: Dosage form units with a diameter of more than 7.5mm are reported to have an
increased GRT compared with those with a diameter of 9.9mm.
3. Shape  of  dosage  form:   Tetrahedron  and  ring  shaped  devices  with  a  flexural
modulus of 48 and 22.5 kilo pounds per square inch (KSI) are reported to have better
GRT @ 90% to 100% retention at 24 hours compared with other shapes.
4. Single  or  multiple  unit  formulation:  Multiple  unit  formulations  show  a  more
predictable release profile and insignificant impairing of performance due to failure
of units, allow co-administration of units with different release profiles orcontaining
incompatible substances and permit a larger margin of safety against dosage form
failure compared with single unit dosage forms.
5. Fed or unfed state: Under fasting conditions, GI motility is characterized by periods
of strong motor activity or the migrating myoelectric complex (MMC) that occurs
every 1.5 to 2 hours. The MMC sweeps undigested material from the stomach and, if
the timing of administration of the formulation coincides with that of the MMC, the
GRT of the unit can be expected to be very short. However, in the fed state, MMC is
delayed and GRT is considerably longer.
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6. Nature of meal:  feeding of indigestible polymers or fatty acid salts can change the
motility pattern of the stomach to a fed state, thus decreasing the gastric emptying
rate and prolonging drug release.
7. Caloric content: GRT can be increased by 4 to 10 hours with a meal that is high in
proteins and fats.
8. Frequency of feed:  the GRT can increase by over 400 minutes,  when successive
meals are given compared with a single meal due to the low frequency of MMC.
9. Gender:  Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with their
age and race matched female counterparts (4.6±1.2 hours), regardless of the weight,
height and   body surface.
10. Age: Elderly people, especially those over 70 years, have a significantly longerGRT.
11. Posture: GRT can vary between supine and upright ambulatory states of the patients.
12. Concomitant   drug   administration:   Anticholinergics   like   atropine   and
propantheline,  opiates like codeine and prokinetic agents like metoclopramide and
cisapride13
Timmermans et al studied the effect of buoyancy, posture, and nature of meals on the
gastric  emptying  process  In  vivo  using  gamma  scintigraphy.  To  perform  these  studies,
floating and nonfloating capsules of 3 different sizes having a diameter of 4.8 mm(small
units), 7.5mm(medium units), and 9.9 mm (large units), were formulated14. On comparison
of floating and nonfloating dosage units, it was concluded that regardless of their sizes the
floating dosage units remained buoyant on the gastric contents throughout their residence in
the gastrointestinal tract, while the non floating dosage units sank and remained in the lower
part of the stomach. Floating units away from the gastroduodenal junction were protected
from the peristaltic waves during digestive phase while the non floating forms stayed close to
the pylorus and were subjected to propelling and retropelling waves of the digestive phase
(Figure 3). It was also observed that of the floating and non floating units, the floating units
were had a longer gastric residence time for small and medium units while no significant
difference was seen between the two types of large unit dosage forms.15
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Fig No. 3:  Intragastric residence positions of floating and non floating units.
Gastro Retentive Drug Delivery System
Transit of formulation through GIT will determine how long a compound will be in
contact with its preferred absorptive site. Absorption windows in proximal gut can limit the
bioavailability of orally administered compounds and can be major obstacle in development
of  controlled  release  formulations5.  Two  main  approaches  to  increase  residence  of  drug
formulations at or above absorption window which have been presently explored:
i) Bioadhesive microspheres that have slow intestinal transit.
ii) Gastro retentive dosage system which is based on multiparticulates or large single
unit system.
An elegant and simple way to improve drug absorption is to hold a drug delivery
system above the absorption window and for  drug to  be released at  an appropriate  rate.
Because most absorption windows are thought to be located in proximal small intestine, the
obvious strategy will be to hold formulation in stomach (gastro retention)16
Pharmaceutical  dosage  forms  with  gastro  retentive  property  would  enable  an
extended  absorption  phase.  After  oral  administration,  dosage  form would  be  retained  in
stomach for several hours and release drug there, in a controlled and prolonged manner, so
that drug could be supplied continuously to its absorption sites in upper GIT.
Gastroretention helps  to  provide  better  availability of  new products  with suitable
therapeutic activity and substantial benefits for patients. This mode of administration would
best achieve the known pharmacokinetic and pharmacodynamic advantages of CR-DFs of
these drugs17.
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Criteria for Selection of Drug Candidate for GRDF 
In  general,  appropriate  candidates  for  CR-GRDF  are  molecules  that  have  poor
colonic absorption but are characterized by better absorption properties at the upper parts of
the GIT.
1. Absorption from upper GIT: Drugs have a particular site for maximum absorption
e.g. ciprofloxacin, whose maximum absorption is in the stomach only.
2. Drugs having low pKa, which remains unionized in stomach for better absorption.
3. Drugs having reduced solubility at higher pH e.g. captopril and chlordiazepoxide.
4. Local  action  as  it  is  seen  in  the  treatment  of  H.pyloriby  amoxicillin  and
misoprostol as in case of ulcers. The bioavailability of drugs that get degraded in
alkaline pH can be increased by formulating gastro retentive dosage forms. E.g.
doxifluridine, cefpodoxime proxetil, which degrades in small intestine.
5. To minimize gastric irritation which may be caused by sudden increase of drug
concentration in the stomach.e.g. NSAIDs.
6. Improve effectiveness of particular drugs.  e.g. Antibiotics in the colon tend to
disturb the microflora causing overgrowth of  microorganisms like Clostridium
difficile causing colitis.
7. Drugs that degrade in the colon, e.g., ranitidine HCl and metronidazole14.
Advantages of Gastroretentive Drug Delivery Systems
1. Enhanced  bioavailability:Thebioavailability  of  riboflavinCR-GRDFis  significantly
enhanced  incomparison  to  the  administration  of  non-GRDF  CR  polymeric
formulations.
2. Enhanced  first-pass  biotransformation:  The  pre-systemic  metabolism  of  the
tested  compound  may  be  considerably  increased  when  the  drug  is  presented  to
themetabolic  enzymes  (cytochrome  P450,  in  particular  CYP3A4)  in  a  sustained
manner, rather than by a bolus input.
3. Sustained  drug  delivery/reduced  frequency  of  dosing:  For  drugs  with  relatively
short biological halflife,sustained and slow input from CR-GRDF may result in a flip-
flop  pharmacokinetics  and  enable  reduced  dosing  frequency.  This  feature  is
associated with improved patient compliance, and thereby improves therapy.
4. Targeted therapy for local ailments in the upper GIT.
5. Reduced fluctuations of drug concentration.
6. Improved selectivity in receptor activation.
7. Reduced  counter-activity  of  the  body:  Inmanycases,thepharmacological  response
Ultra College of Pharmacy, Madurai PAGE 11
INTRODUCTION
which intervenes with the natural physiologic processes provokes a rebound activity
of the body that minimizes drug activity. Slow input of the drug into the body was
shown to minimize the counter activity leading to higher drug efficiency.
8. Extended time over critical  (effective) concentration:  For certain drugs that have
non-concentration dependent pharmacodynamics, such as betalactam antibiotics, the
clinical  response  is  not  associated  with  peak  concentration,  but  rather  with  the
duration of  time over  a  critical  therapeutic  concentration.  The sustained mode of
administration enables extension of the time over a critical concentration and thus
enhances the pharmacological effects and improves the clinical outcomes.
9. Minimized adverse activity at the colon: This pharmacodynamic aspect provides the
rationale for  GRDF formulation for beta-lactam antibiotics that  are absorbed only
from the small intestine, and whose presence in the colon leads to the development of
microorganism’s resistance.
10. Site specific  drug delivery:  The controlled,  slow delivery of  drug to the stomach
provides sufficient local therapeutic levels and limits the systemic exposure to the
drug.reduces side effects that are caused by the drug in the blood circulation18.
Disadvantages of gastroretentetive system
There are certain situations where gastric retention is not desirable. Aspirin and non-
steroidal anti-inflammatory drugs are known to cause gastric lesions and slow release of such
drugs in the stomach is unwanted. Thus drugs that may irritate the stomach lining or are
unstable  in  acidic  environment  should  not  be  formulated  as  gastroretentive  system.
Furthermore,  other  drug  such  as  Isosorbidedinitrate,  that  are  absorbed  equally  well
throughout the GI tract will not benefit by incorporation into a gastric retention system19.
Also GRDF’s have some limitations such as:
1. Requirement of high level of fluids in stomach for the delivery system to float and
work efficiently. Drugs, which undergo significant first pass metabolism, may not be
desirable candidate for FDDS since the slow GE may lead to systemic bioavailability.
2. Requires the presence of food to delay gastric emptying.
3. Drugs  having  solubility  or  stability  problems  in  the  highly  acidic  gastric
environment or which are irritant to gastric mucosa cannot be formulated as GRDDS.
4. Gastric emptying of floating dosage forms in supine subjects may occur at random
and becomes highly dependent on the diametric size. Therefore, patients cannot be
dosed these formulations just before going to bed.
5. On  the  other  hand,  violent  gas  generation,  disintegration  of  dosage  forms,  burst
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release, dose dumping and alkaline microenvironment are the limitations of floating
alginate beads.
6. In case of bioadhesive systems, the acidic environment, thick mucous as well as high
turnover rate of mucous prevents bond formation at the mucous-polymer interface.
7. For swellable systems, the dosage forms must maintain size larger than the aperture
of the resting pylorus for required time period20.
Approaches to Gastric Retention 
A number of approaches have been used to increase gastric retention time (GRT) of a
dosage form in stomach by employing a variety of concepts. These include:
(a) Low density form of the DF that causes buoyancy in gastric fluid. (b) High density DF
that is retained in the bottom of the stomach.
(c) Bio / Mucoadhesive drug delivery system. (d) Swelling and expanding system.
(e) Incorporation of passage delaying food agents. (f) Ion exchange resin.
(g) Osmotic regulated systems. (h) Raft systems.3
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a) Floating systems
Floating drug delivery systems (FDDS) have a bulk density less than gastric fluids
and so remain buoyant in the stomach without affecting gastric emptying rate for a prolonged
period of time. While the system is floating on the gastric contents, the drug is  released
slowly at  the desired rate  from the system. After  release of  drug,  the residual  system is
emptied from the stomach. This  results  in an increased GRT and a better  control  of the
fluctuations in plasma drug concentration. FDDS can be divided into non-effervescent and
effervescent systems.
b) High density systems
Sedimentation has been employed as a retention mechanism for pellets that are small
enough to be retained in the rugae or folds of the stomach body near the pyloric region,
which is the part of the organ with the lowest position in an uprightposture. These systems
have a density of about 3 g/cm3 and are capable of withstanding  its  peristaltic  movements.
A  density  of  2.6-2.8  g/cm3   acts  as  a threshold  value  after  which  system  can  be
retained  in  the  lower  parts  of  thestomach. High-density formulations include coated
pellets. Coating is done by heavy inert material such as barium sulphate, zinc oxide, titanium
dioxide, iron powder etc.
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c) Bio/Muco-adhesive systems
Bioadhesive drug delivery systems (BDDS) are used as a delivery device within the
lumento enhance drug absorption in a site specific manner. This approach involves the use of
bioadhesive polymers,  which can adhere to the epithelial surface in the stomach offering
possibility of creating an intimate and prolonged contact at site of administration resulting in
enhanced absorption and and in combination with a controlled release of drug also improved
patient compliance  by  reducing  the  frequency  of  administration. Some  of  the  most
promising excipients that have been used commonly in these systems include polycarbophil,
carbopol, lectins, chitosan and gliadin, etc.
Binding of polymers to mucin/epithelial surface can be divided into three broad 
categories
• Hydration-medicated adhesion.
• Bonding-medicated adhesion.
• Receptor-medicated adhesion.
d) Swelling and expanding system
This type of system, after swallowing, swells unrestrained via imbibitions of gastric
fluid to an extent that it prevents their exit from the stomach. These systemsmay be referred
to as the ‘plug-type systems’ since they have a tendency to remain lodged near the pyloric
sphincter.They reach a significantly larger size in the stomach due to swelling or unfolding
processes that prolong their GRT. After drug release, their dimensions are minimized with
subsequent evacuation from the stomach.
e) Incorporation of passage delaying food agents
Food excipients like fatty acids e.g. salt of myristic acid change and modify the pattern
of  stomach  to  a  fed  state,  thereby  decreasing  gastric  emptying  rate  and  permitting
considerable prolongation of release. The delay in gastric emptying after meals rich in fats is
largely caused by saturated fatty acids with chain length of C10- C14.
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f) Ion exchange resin
A coated ion exchange resin bead formulation has been shown to have gastric retentive
properties,  which  was  loaded  with  bicarbonates.  Ion  exchange  resins  are  loaded  with
bicarbonate and a negatively charged drug is bound to the resin. The resultant beads were
then encapsulated in a semi-permeable membrane to overcome the rapid loss of CO2. upon
arrival in the acidic environment of the stomach, an exchange of chloride and bicarbonate
takes  place.  As  a result  of  this reaction CO2  was released and trapped in the membrane
thereby carrying beads toward the top of gastric content and producing a floating layer of
resin beads in contrast the uncoated beads, which will sink quickly21.
g) Osmotic regulated systems
It is comprised of an osmotic pressure controlled drug delivery device and an inflatable
floating support in a bioerodible capsule. In the stomach the capsule quickly disintegrates to
release the intra gastric osmotically controlled drug deliverydevice. The inflatable support
inside forms a deformable hallow polymeric bag that contains a liquid that gasifies at body
temperature to inflate the bag. The osmotic controlled drug delivery device consists of two
compartment- drug reservoir and osmotically active compartment.
h) Raft forming system
Raft  forming  systems  have  received  much  attention  for  the  delivery  of antacids
and drug delivery for gastrointestinal infections and disorders. The mechanism involved in
the raft  formation includes  the formation of  viscous cohesive gel  in contact  with gastric
fluids, wherein each portion of the liquid swells forming a continuous layer called a raft. This
raft floats on gastric fluids because of low bulk density created by the formation of CO2.
Usually,  the system contains a gel forming agent and alkaline bicarbonates or carbonates
responsible for the formation of CO2 to make the system less dense and float on the gastric
fluids. Jorgen et al described an antacid raft forming floating system. The system contains a
gel forming agent (e.g. alginic acid), sodium bicarbonate and acid neutralizer, which forms a
foaming sodium alginate gel (raft) when in contact with gastric fluids. The raft thus formed
floats on the gastric fluids and prevents the reflux of the gastric contents (i.e. gastric acid)
into the esophagus by acting as a barrier between the stomach and esophagus22.
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Floating Drug Delivery Systems (FDDS) 
From the formulation  and technological  point  of  view,  the floating drug delivery
systems are considerably easy and logical approach in the development of gastro retentive
dosage forms (GRDFs).
Approaches to Design Floating Drug Delivery System
The following approaches have been used for the design of floating dosage forms of 
single and multiple-unit systems3.
Classification of FDDS
Based on the mechanism of buoyancy, two distinctly different technologies have been
utilized in development of FDDS, which are:
A) Effervescent system
Effervescent  system include  use  of  gas  generating  agents,   carbonates   (ex.
Sodium bicarbonate) and other organic acid (e.g. Citric acid and tartaric acid) present in the
formulation to produce carbon dioxide (CO2) gas, thus reducing the density of the system
and making it to float on the gastric fluid. The optimal stoichiometric ratio of citric acid and
sodium bicarbonate for gas generation is reported to be 0.76:1. Effervescent systems have
been further classified into two types.
I) Gas generating system
a) Intra gastric single layer floating tablets
These systems are formulated by intimately mixing CO2  generating agents and the
drug along with polymers and compressed as a matrix tablet. These have bulk density lower
than  gastric  fluids  and  therefore  remain  floating  in  the  stomach  unflattering  the  gastric
emptying rate for a prolonged period. The drug is slowly released at a desired rate from the
floating system and after complete release the residual system is expelled from stomach. This
leads  to  an  increase  in  GRT  and  a  better  control  over  fluctuations  in  plasma  drug
concentration.
Talwaret  al  prepared  a  once-daily  formulation  for  oral  administration  of
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ciprofloxacin. The formulation was composed of 69.9% ciprofloxacin base, 0.34%sodium
alginate,  1.03%  xanthum  gum,  13.7%  sodium  bicarbonate,  and  12.1% cross-linked poly
vinyl pyrrolidine. The cross linked PVP initially and the gel forming  polymers  later  formed
a  hydrated  gel  matrix  that  entrapped  the  gas, causing the tablet to float and be retained in
the  stomach The hydrated  gel  matrix  created  a  diffusion  path  for  the  drug,  resulting in
sustained release of the drug.
b) Intra gastric bilayered floating tablets
It contains the gas generating mechanism in one hydrocolloid containing layer and
drug in other layer formulated for SR effect.
Ozdemiret al prepared floating bilayer tablets with controlled release for furosemide.
The  low  solubility  of  the  drug  could  be  enhanced  by  using  the kneading method,
preparing a solid dispersion with β cyclodextrin mixed in a 1:1 ratio. One layer contained the
polymers HPMC 4000, HPMC 100, and CMC (for the control of the drug delivery) and the
drug. The second layer contained the effervescent mixture of sodium bicarbonate and citric
acid.
c) Multiple Unit type floating pills
Ichikawa  et  al  developed  a  new  multiple  type  of  floating  dosage  system having
a pill in the core, composed of effervescent layers and swellable membrane layers coated on
sustained release pills (shown in figure 5). The inner layer of effervescent agents containing
sodium bicarbonate and tartaric acid was divided into 2 sublayers to avoid direct  contact
between the 2 agents. These sublayers were surrounded by a swellable polymer membrane
containing polyvinyl acetate and purified shellac. When this system was immersed in the
buffer at 37ºC, it settled down and the solution permeated into the effervescent layer through
the outer swellable membrane. CO2  was generated by the neutralization reaction between
the2 effervescent agents, producing swollen pills (like balloons) with a density less than 1.0
g/ml.
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Fig No. 5: Multiple unit type floating pill with different layers.
II)  Volatile Liquid / Vacuum Containing System
a) Inflatable gastrointestinal delivery systems
In these systems an inflatable chamber is incorporated, which contains liquid e.g. ether,
cyclopentane,  that  gasifies  at  body  temperature  to  cause  the  chamber  to  inflate  in  the
stomach.These  systems  are  fabricated  by loading  the  inflatable  chamber   with   a   drug
reservoir,  which  can  be  a  drug,  impregnated  polymeric matrix,  then  encapsulated  in  a
gelatin   capsule.   After   oral   administration,   the  capsule  dissolves  to  release  the  drug
reservoir together with the inflatable chamber. The inflatable chamber automatically inflates
and retains the drug reservoir compartment in the stomach. The drug is continuously released
from the reservoir into the gastric fluid.This system shown in figure 6.
Fig No. 6:  Inflatable gastrointestinal delivery systems
Ultra College of Pharmacy, Madurai PAGE 19
INTRODUCTION
b) Intragastricosmotically controlled drug delivery system
It  is  comprised  of  an  osmotic  pressure  controlled  drug  delivery  device  and  an
inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly
disintegrates  to  release  the  intragastricosmotically  controlled  drug  delivery  device.  The
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid that
gasifies  at  body temperature  to  inflate  the bag.  The osmotic pressure  controlled  delivery
device consists of two compartments; drug reservoir compartment and an osmotically active
compartment.
The drug reservoir compartment is enclosed by a pressure responsive collapsible bag,
which  is  impermeable  to  vapour  and  liquid  that  come  out  from  delivery  orifice.  The
osmoticallyactive compartment contains an osmotically active salt  and is  enclosed within
semipermeable housing. In the stomach, water in the GI fluidis continuouslyabsorbedthrough
the semipermeable membrane into osmotically active compartment to dissolve the osmotic
salt. An osmotic pressure is thus created which acts on the collapsible bag and in turn forces
the drug reservoir compartment to reduce its volume and activate the drug release of drug
solution formulation through the delivery orifice.
The floating support is also made to contain a bioerodible plug that erodes after a
predetermined time to deflate the support. The deflated drug delivery systemis then emptied
from the stomach. This system is shown in figure 7.
Fig No. 7:   Intragastricosmotically controlled drug delivery system
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B. Non effervescent systems
The Non effervescent FDDS is based on swelling mechanism of polymer or bioadhesion
to mucosal layer in GI tract. The most commonly used excipients in non-effervescent FDDS
are gel forming or highly swellable cellulose type hydrocolloids, polysaccharides and matrix
forming material such as polycarbonate, polyacrylate, polymethacrylate, polystyrene as well
as bioadhesive polymer such as chitosan and carbopol17.
The various type of this systemsare as follows
1. Colloidal gel barrier or Hydrodynamically balanced system (HBS)
It  was  first  designed  by Sheth  and  Tossounian  in  1975.  These  systems  are  able  to
maintain their low apparent density, while the polymer hydrates and builds a gelled barrier at
outer  surface.  The air  trapped  by swollen polymer maintains  density less  than unity and
confors buoyancy. The drug is released progressively fromswollen matrix. E.g. gel forming
highly swellable cellulose type hydrocolloids: HEC, HPMC, NaCMC, Polysacchacarides and
matrix forming polymers such as polycarbophil, polyacrylates and polystyrene.
2. Single layer floating tablets
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid which
swell in contact with gastric fluid and maintain bulk density of less than unity. The air trapped
by the swollen polymer confers buoyancy to these dosage forms.
3. Bilayered floating tablets
A  bilayered  tablet  contain  two  layer-  one  immediate  release  layer  which release
initial  dose  from system and another  sustained release  layer  which absorbs  gastric  fluid,
forming an impermeable colloidal gel barrier on its surface. Since the bulk density of system
is less than unity, it remains buoyant in stomach.
4. Microporous compartment system
Fluid- filled floating chamber   which includes incorporation of a gas-filled floatation
chamber into a microporous component that houses a drug reservoir. Apertures or openings
are present  along the top and bottom walls  through which the gastrointestinal  tract  fluid
enters to dissolve the drug. The other two walls in contact with the fluid are sealed so that the
undissolved drug remains therein. TheFluid present could be air, under partial vacuum or any
other  suitable  gas,  liquid,  or  Solid  having  an  appropriate  specific  gravity  and  an  inert
behaviour.
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Fig No. 8: Gas filled floatation chamber.
5. Alginate beads
Multi unit floating dosage forms were developed from freeze-dried calcium alginate.
Spherical  beads of  approximately 2.5 mm diameter  can be prepared by dropping sodium
alginate solution into aqueous solution of calcium chloride, causing precipitation of calcium
alginate leading to formation of porous system, which can maintain a floating force for over
12 hours. These floating beads provide prolonged residence time of more than 5.5 hour.
6. Hollow microspheres
Hollow microspheres (microballons) loaded with drug in their outer polymer shell
were prepared by a novel emulsion-solvent diffusion method. The ethanol: dichloromethane
solution of the drug and a enteric acrylic polymer is poured into an agitated aqueous solution
of PVA that was thermally controlled at 40ºC. The gas phase generated in dispersed polymer
droplet  by evaporation  of  dichloromethane  formed  an  internal  cavity  in  microspheres  of
polymer with drug. The microballonsfloated  continuously  over  the  surface  of  acidic
dissolution  media  containing surfactant for more than 12 hours In vitro18.
Advantages of Hollow Microspheres
1. Improves patient compliance by decreasing dosing frequency.
2. Bioavailability enhances despite first pass effect because fluctuations in plasma drug
concentration  is  avoided,  a  desirable  plasma drug  concentration  is  maintained  by
continuous drug release.
3. Gastric retention time is increased because of buoyancy.
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4. Enhanced absorption of drugs which solubilise only in stomach
5. Drug releases in controlled manner for prolonged period.
6. Site-specific drug delivery to stomach can be achieved.
7. Superior to single unit floating dosage forms as such microspheres releases drug 
uniformly and there is no risk of dose dumping.
8. Avoidance of gastric irritation, because of sustained release effect.
9. Better therapeutic effect of short half-life drugs can be achieved.
Mechanism of Floating Microspheres
When  microspheres  come  in  contact  with  gastric  fluid  the  gel  formers,
polysaccharides, and polymers hydrate to form a colloidal gel barrier that controls the rate of
fluid penetration into the device and consequent drug release. As the exterior surface of the
dosage  form  dissolves,  the  gel  layer  is  maintained  by  the  hydration  of  the  adjacent
hydrocolloid layer. The air trapped by the swollen polymer lowers the density and confers
buoyancy to the microspheres. However a minimal gastric content needed to allow proper
achievement of buoyancy21, 22. Hollow microspheres of acrylic resins,  eudragit,  polyethylene
oxide,  and  cellulose  acetate;  polystyrene  floatableshells; polycarbonate floating balloons
and gelucire floating granules are the recent developments21.
List Of Polymers Used In Hollow Microspheres
Cellulose acetate,  Chitosan,  Eudragit,  Acrycoat,  Methocil,  Polyacrylates,  Polyvinyl
acetate, Carbopol  , Agar, Polyethylene oxide, Polycarbonates, Acrylic resins and Polyethylene
oxide.
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Table No. 2: Various Types of Floating Drug Delivery Systems studied
Name of formulation Name of drug
Tablets
Capsules
Microspheres/Floating 
beads
Granules
Ampicillin,  Atenolol,  Amoxycillin,  Acetyl  salicylic
acid,  Acetaminophen,  Chlorpheniramine  maleate,
Ciprofloxacin,  captopril,  Cinnarazine,  Dilitazem,
Fluoruracil,  Isosorbide  di  nitrate,  Riboflavin,
Prednisolone, Theophilline.
Nicardepine,  Diazepam,  Misoprostol,  Propranolol,
Verapamil.
Aspirin,  Verapamil,  Ibuprofen,  Ketoprofen,
Amoxicillin,   Riboflavin,   Meloxicam,  Nicardepine
etc.
Indomethacin,Diclofenac,
Prednisolone23.
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Table No. 3: Marketed products of GRDFs
SR.NO. BRAND
NAME
DRUG (DOSE) COMPANY,
COUNTRY
REMARKS
1. Madopar® Levodopa (100
mg)
Benserazide
Roche
Products,USA
Floating CR
capsule
2. Valrelease® Diazepam
(15mg)
Hoffmann-
LaRoche,USA
Floating
Capsule
3. Liquid
Gaviscon®
Al hydroxide (95
mg), Mg carbonate
(358 mg)
GlaxoSmithKline
, India
Effervescent
floating
liquid
alginate
4. Topalkan® Al-Mg antacid Pierre Fabre
Drug, France
Floating
liquid
alginate
5. Conviron Ferrous sulphate Ranbaxy, India forming
FDDS
6. Cifran OD® Ciprofloxacin
(1mg)
Ranbaxy, India Gas-
generating
floating
7. Cytotec® Misoprostol (100
mcg/200 mcg)
Pharmacia, USA Bilayer
floating
capsule
8. Oflin OD® Ofloxacin (400
mg)
Ranbaxy, India Gas-
generating
floating
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A.H. El-Kamel et al., (2000) prepared the Ketoprofen floating oral delivery system by the
emulsion  solvent  diffusion  technique.  Four  different  ratios  of  Eudragit  S100  (ES)  with
Eudragit RL (ERL) were used to form the floating microparticles. The drug retained in the
floating microparticles decreased with increase in ERL content.  All  floating microparticle
formulations showed good flow properties  and packability.  Scanning electron microscopy
and  particle  size  analysis  revealed  differences  between  the  formulations  as  to  their
appearance and size distribution. X-ray and DSC examination showed the amorphous nature
of the drug41.
K
umaresh S et al, (2001) investigated the release characteristic of hollow microspheres of
cellulose  acetate  loaded  with  four  cardiovascular  drugs  (nifedipine  [NFD],  nicardapine
hydrochloride [NCD], verapamil hydrochloride [VRP], and dipyridamole [DIP]) prepared by
a novel solvent diffusion evaporation method. They found that yield of microspheres was
80% and microspheres tended to float over the gastric media for more than 12 hr. The release
of  the  drug  was  controlled  for  more  than  8  hr.  Finally  they  concluded  that  drugs  like
nifidipine  and  nicardipine  hydrichloride  can  be  delivered  for  effective  management  of
hypertension35.
Sato Y et  al, (2003) Prepared  and evaluated riboflavin  containing  microballoons  for
floating   controlled   drug   delivery  system  in  healthy  humans.  They   observed  strong
correlation between the buoyancy and excretion half-life (t1/2) and   riboflavin release from
the microballoons    and total urinary  excretion.  Finally they concluded  that the intragastric
floating  properties  of  microballoons  are  likely  to  be  beneficial  as  far  as  a  sustained
pharmacological action is concerned26.
Yasunori sato et al,
 (2004) Reported on the floating and drug releasing behaviors of hollow
microspheres   (microballoons)   prepared   by  the  emulsion   solvent diffusion method.
Microballoons were prepared by   utilizing enteric acrylic polymers codissolved with drug in
a mixture of dichloromethane and ethanol. The release   properties   of five different   drugs
exhibiting   distinct water solubilities (aspirin, salicylic acid, ethoxybenzamide, indomethacin
and  riboflavin)  entrapped  within  microballoons  were  investigated.  They  concluded  that
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Buoyancy of the microballoons decreased with increasing drug release rate.  In  the  case  of
aspirin,  salicylic  acid  and  ethoxybenzamide,  the  drug release profiles of microballoons
proved a linear relationships by Higuchi plotting. In addition, by incorporating a polymer
such as hydroxypropylmethylcellulose  within the shell of microballoons,  the release rate   of
riboflavin   from   the   microballoons   could   be   controlled   while maintaining high
buoyancy32.
Jain SK et al, (2005) prepared porous carrier based floating granular delivery system of
Repaglinide  using  calcium  silicate  as  porous  carrier,  HPMC  K4M,  ethyl  cellulose  and
carbopol 940 as matrix forming polymers and evaluated for its gastro retentive and controlled
release properties, particle morphology, micromeritic properties, invitro floating behaviour,
drug content (%), invitro drug release, comparison with marketed capsule and invivo study in
albino rat52.
       
Streubel A et al, (2006) developed  and  evaluated  a  novel preparation  method  for  floating
microparticles  consisting  of  polypropylene foam powder,  of chlorpheniramine maleate,
diltiazem HCl and theophylline or verapamil HCl) as model drugs with    polymers like
eudragit RS or polymethacrylate. They concluded that new preparation methods have short
processing time, no exposure of ingredient to high temperature and avoid use of toxic organic
solvent, no drug loss and encapsulation  efficiency close to 100%28.
Patel  A  et.al.  (2006)  prepared  and  optimized  the  floating  microspheres  of  metformin
hydrochloride using ethyl cellulose and concluded that the developed floating microspheres
of metformin hydrochloride may be used in clinic for prolonged drug release in stomach for
at least 8 hrs, thereby improving the bioavailability and patient compliance34.
Shraddha S. Badve et al., (2006) developed porous calcium pectinate beads for floating-
pulsatile drug delivery. The floating beads obtained were porous (34% porosity), hollow with
bulk density <1 and had t50% of 14-24 h. In-vivo studies by gamma scintigraphy determined
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on rabbits showed gastroretention of beads up to 5 h41.
Ramesh.R.Putheti1 et al, (2009) reviewed Pharmaceutical Formulation and development  of
Floating  and  Swellable  sustained  drug  delivery  systems various parameters affecting the
behavior of floating and swelling multiparticulate  in oral dosage  form summarizes  the in
vitro techniques,  in vivo  studies  to  evaluate  the  performance  and  application  of  floating
and swellable systems, and applications of these systems. These systems are useful to several
problems encountered during the development of a pharmaceutical dosage form.  From the
formulation and technological point of view, the floating and swellable drug delivery systems
are considerably easy and logical approach. An attempt has been made in this review article
to introduce scientists to the current technological developments in floating and swellable
drug delivery system37.
Rajinikanth  PS,  (2009)  et  al., developed  a  stomach-specific  drug  delivery  system  for
controlled  release  of  clarithromycin  for  eradication  of  Helicobacter  pylori  (H.  pylori).
Floating-bioadhesive  microspheres  of  clarithromycin  (FBMC)  were  prepared  by
emulsification-solvent  evaporation  method  using  ethylcellulose  as  matrix  polymer  and
Carbopol  934P as  mucoadhesive  polymer.  The  prepared  microspheres  were  subjected  to
evaluation for particle size, incorporation efficiency, in vitro buoyancy, in vitro mucoadhesion
and  in  vitro  drug  release  characteristics.  The  prepared  microspheres  showed  a  strong
mucoadhesive  property  with  good  buoyancy.  The  formulation  variables  like  polymer
concentration and drug concentration influenced the  in  vitro  drug release significantly in
simulated gastric fluid (pH 2.0). The in vivo H. pylori clearance efficiency of prepared FBMC
in reference to clarithromycin suspension following repeated oral administration to H. pylori
infected Mongolian gerbils was examined by polymerase chain reaction technique and by a
microbial culture method. The FBMC showed a significant anti-H. pylori effect in the in vivo
gerbil model. It was also noted that the required amount of clarithromycin for eradication of
H.  pylori  was  significantly  less  in  FBMC  than  from  corresponding  clarithromycin
suspension. The result further  substantiated  that  FBMC  improved  the  gastric  stability  of
clarithromycin (due to entrapment within the microsphere) and eradicated H. pylori from  the
gastrointestinal  tract  more  effectively  than  clarithromycin  suspension because of the
prolonged gastrointestinal residence time of the formulation33.
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Vishal  G Karkhile et  al.,  (2009) prepared  the floating tablets  of  Furosemide by direct
compression  technique.  The tablets  were  evaluated  for  in-vitro buoyancy and  dissolution
studies. Tablets were evaluated for physical characteristics viz. Hardness, floating capacity,
thickness, swelling index, and weight variation. Further, tablets were evaluated for  in-vitro
release characteristic for 8 hours. The data of  in-vitro dissolution study shows that the zero
order plots were found to be fairly linear as indicated by their high regression value (R2 =
0.9772 to 0.9911)40.
Shah S.H et al, (2011) reviewed on the stomach specific floating drug delivery system: a
review It is known that differences in gastric physiology, such as, gastric pH, and motility
exhibit  both  intra-as  well  as  inter-subject  variability  demonstrating  significant  impact  on
gastric retention time and drug delivery behaviour.   This triggered   the attention   towards
formulation   of stomach specific (gastro retentive) dosage forms. This dosage forms will be
very  much  useful  to  deliver  ‘narrow  absorption  window’ drugs.  Several  approaches  are
currently utilized in the prolongation of the GRT, including floating drug delivery systems
(FDDS),  swelling  and  expanding  systems,  polymeric  bioadhesive  systems,  high-density
systems, modified-shape systems and other delayed gastric emptying devices. In this review,
current & recent developments of Stomach Specific FDDS are discussed36.
N.V.Satheesh Madhav, (2011)  reviewed on various aspects of the microparticulate drug
dlivery system including method of formation, evaluation and characterization43.
Yogesh Garg et al, (2011) prepared the purified microparticles of Pravastatin sodium use for
intestinal  delivery.  Microparticles formed were discrete,  free flowing, and exhibited good
mucoadhesive properties. DSC and DRS showed stable character of drug in microparticles
and  absence  of  drug  polymer  interaction.  The  drug  to  polymer  ratio  and  surfactant
concentration  had  significant  effect  on  mean  particle  size,  drug  release,  and  entrapment
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efficiency. In-vitro permeation studies on goat intestinal mucosa demonstrated a flux rate that
was 169 times higher than the flux of pure drug42.
Ashish  Gupta  et  al, (2012)  prepared  the  Repaglinide  microspheres  by  Quasi  emulsion
solvent  diffusion  technique.  The  microspheres  were  formulated  by  using  various
concentration of HPMCP, Ethyl cellulose and Eudragit RSPO as a retarding agent to controll
the  release  rate.  The  prepared  microspheres  were  evaluated  for  Flow  behaviour,
Compatibility  study,  Drug  entrapment  efficiency, In-vitro dissolution,  Scanning  electron
microscopy  and  particle  size  analysis. In-vitro release  studies  indicated  that,  as  the
concentration  of  retarding  agent  increases  release  from  the  formulation  become  more
sustained38.
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  To develop oral drug delivery systems, it is necessary to optimize both the residence
time of system within the gastrointestinal tract and release of drug from the system. Gastric
emptying of dosage form is an extremely variable process and ability to prolong and control
the emptying time is a valuable asset for dosage form. Gastro retentive systems can remain in
the gastric region for several hours and hence significantly prolong the gastric residence time
of drug and  improves bioavailability, reduces drug waste and improves solubility, of drug
that are less soluble in a high pH environment.
Clarithromycin is an advanced generation macrolide antibiotic used in treatment of H.
Pylori. Besides multi-antibiotic therapy, one of the strategies that can completely eradicate
H.pylori from the stomach and improve the efficacy is to deliver the antibiotic locally in the
stomach  by  increasing  residence  time  of  antibiotics  at  infected  site.  Another  way  is  to
improve the  stability  of  an  antibiotic  in  gastric  environment.  The antibiotics  with  better
stability and longer residence time will allow more of the antibiotic to penetrate through the
gastric mucus layer to act effectively on H.pylori. Then clarithromycin penetrates bacteria
cell wall and reversibly binds to domain V of the 23S ribosomal RNA of the 50S subunit of
the bacterial ribosome, blocking translocation of aminoacyl transfer-RNA and polypeptide25
  The  controlled  gastric  retention of  solid  dosage  forms may be  achieved  by the
mechanism of mucoadhesion, flotation, sedimentation, expansion, modified shape system or
by the simultaneous administration of pharmacological agents that delay gastric emptying.
Floating microparticls are gastro retentive drug delivery systems based on non- effervescent
approach.  These  microparticles  are  characteristically  free flowing  powders  and  remain
buoyant over gastric contents for prolonged period. As the system floats over gastric contents,
the drug is released slowly at desired rate resulting in increased gastric retention with reduced
fluctuations in plasma drug concentration. Drugs having short half life are eliminated quickly
from the blood circulation and hence require frequent dosing. To avoid this, release of drug
will be made slowly in the gastrointestinal tract and maintain effective drug concentration in
the serum for longer period of time30.
A controlled release system designed to increase its residence time of clarithromycin
in the stomach can be achieved through the preparation of floating delivery systems either
tablets or microspheres. 
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Floating multiparticulate dosage form have been prepared by solvent diffusion and solvent
evaporation method to create an hollow inert core (26, 27). Porous calcium pectinate beads with
bulk density less than 1 were prepared by Badve SS. Alternatevely floating microparticles
based on low density foam powder were prepared with polypropylene foam powder, matrix
forming polymer and the drug (Verapamil HCL)28. Instead of foam powder highly porous
carrier material like calcium silicate was used along with Eudragit S to deliver Repaglinide
over an extend period of time.
           In the present study, colloidal silicon dioxide (Aerosil) was used as the porous
material.  Colloidal  silicon  dioxide  is  hygroscopic  but  adsorbs  large  quantities  of  water
without liquefying29.  One study reveals the use of calcium silicate as porous carrier.  The
present study was aimed at using colloidal silicon dioxide as porous carrier for preparing
floating microparticles of Clarithromycin whose physiochemical properties and short half life
make it suitable candidate for floating drug delivery system31.
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OBJECTIVE OF THE WORK
                 The main objectives of the present work are
• To prepare the floating microparticles of the Clarithromycin with the use of polymer-
ethyl cellulose, aerosil and different solvents (dichloromethane & ethanol).
• To evaluate  the  formulated  floating  microparticles  for  various  characteristics  and
properties and to arrive at the optimized formulation based on floating time and in
vitro drug release.
Ultra College of Pharmacy, Madurai PAGE 33 
SCOPE OF THE WORK
PLAN OF WORK
1. Literature  review  to  select  method  of   preparation  of  floating  microparticles  of
Clarithromycin.
2. Preformulation studies
 Determination of Solubility of Clarithromycin.
 Preparation of calibration curve of Clarithromycin.
 FT-IR Spectroscopy.
3. Formulation development of floating microparticles of Clarithromycin.
4. Evaluation of prepared Clarithromycin microparticles.
 Micromeritic Properties of microparticles (particle size, bulk density,  
tapped density, compressibility index, hausners ratio, angle of repose).
  Percent yield of microparticle.
 Drug entrapment efficiency.
 Morphology by SEM.
         Crushing strength..
        In-vitro drug release studies.
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List of Materials
TABLE:4 List of materials
S.No Chemicals & reagents Supplier
1 Clarithromycin RA CHEM pharma
2 Ethyl cellulose S.d Fine- chem. Ltd
3 Colloidal silicon dioxide SRL
4 Dichloromethane SRL
5 Ethanol Trade Co.Ltd made in china 
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List of Instrument/ Equipments
TABLE:5 List of Instruments and uses
S.No Instrument/ Equipment Source
1 Electronic balance Shimadzu corporation, Japan 
2 Mechanical stirrer Remi motors, Mumbai 
3 FT-IR Spectroscopy Perkin Elmer
4 Sieves Jayant scientific Ltd- mumbai
5 Scanning electronic microscope Tescan
6 Phase contrast microscope Bino cxi micron optic
7 T.A.X.T plus Texture Analyser Stable micro system, UK
8 UV-Visible spectro photometer Systronics
9 Dissolution test apparatus Disso 2000 Lab india 
10 Vacuum oven Shivani scientific industries p (Ltd )
Bombay
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DRUG PROFILE
CLARITHROMYCIN
Structure:
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Clarithromycin
Chemical Name: 6-O-methylerythromycin
Empirical formula: C38H69NO13
Molecular Weight: 747.95
Melting Point: 2200C
Description: White or colourless, odourless crystals.
Category: Antibacterial
Storage: Store in a cool, dry place.
Solubility:
It is soluble in chloroform, acetone and dilute acids. Slightly soluble in 
methanol, ethanol and acetonitrile, and practically insoluble in water54.
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Pharmacodynamic Property:
Clarithromycin is a semi-synthetic broad spectrum  macrolide antimicrobial  agent
structurally related to Erythromycin.  It is acid stable and rapidly absorbed  after  oral
administration.
Clarithromycin is bacteriostatic or bacteriocidal  depending  on  the  organism  and
antimicrobial agent concentration. It exerts its antibacterial action by binding to the 50S
ribosomal sub-unit of susceptible bacteria and suppresses protein synthesis. It is highly potent
against a wide variety of aerobic and anaerobic gram- positive and gram-negative organisms
such as S.aureus, S.pneumoniae, H.influenza, Moraxella catarrhalis, and other microorganisms
like Mycobacterium avium complex (MAC) and Helicobacter pylori.
Pharmacokinetic Property:
Absorption: - Clarithromycin is absorbed rapidly from the gastrointestinal tract after oral
administration. The microbiologically active metabolite 14-hydroxy Clarithromycin is formed
by first pass metabolism. Peak concentration  occurs  approximately  2  hrs  after  drug
administration. Steady state peak concentration in plasma are 2 to 3 mg/ml after 2 hours from
a regimen of 500 mg every 12 hours or 2 to 4 hours after two 500 mg extended release tablets
given orally.
Distribution: - Clarithromycin and its active metabolite 14-hydroxy Clarithromycin   distribute
widely   throughout   the   body   and   achieve   high intracellular concentrations. Tissue
concentrations generally exceed serum concentrations. Concentrations in middle ear fluid are
50% higher than simultaneous serum concentrations for both Clarithromycin and the active
metabolite. Protein binding of Clarithromycin ranges from 40-70%.
Elimination:  -  Clarithromycin  is  eliminated  by  renal  and  non-renal  mechanisms.  It  is
metabolized  in  the  liver  to  active  14-hydroxy  metabolite.  The  elimination  half-  lives of
Clarithromycin and 14-hydroxyclarithromycin are approximately 3 to 7 hours and 5 to 9 hours.
The amount of Clarithromycin excreted unchanged in the urine  ranges  from  20%  to  40%
depending  on  the  dose  administered  and formulation.
Therapeutic Uses:
• Used in combination for the treatment of Helicobacter pylori infection and
duodenal ulcer disease.
•   F o r  treatment of upper and lower respiratory tract infections.
• For prevention of disseminated Mycobacterium  avium  complex  (MAC)
infections  in  patients  with  advanced  human  immunodeficiency  virus  (HIV)
infections.
• Uncomplicated skin and skin structure infections like Folliculitis, Cellulitis,
Erysipelas.
Adverse Effects:
The majority of the adverse effects reported were of mild and transient nature like
Diarrhoea, nausea, abnormal taste, dyspepsia, headache, etc.
Dosage and Administration:
Clarithromycin is used orally in a dose of 250 to 500mg twice daily.
Marketed Preparations:
CELEX OD (Abott) 500 mg 
Clarithro ER (Alembic) 500 mg 
URCLAR OD (Novartis) 500 mg 
MACLAR (Gracewell) 500 mg55
EXCIPIENT PROFILE
1. Ethyl cellulose (EC)
Synonyms: Aquacoat E-462, Ethocel, Surelease.
Functional category: Coating agent, tablet binder and viscosity increasing agent.
Structural formula:
Description:  Ethyl cellulose i s  a tasteless, f ree   flowing  white  light  coloured 
powder.
Solubility:
  
1.   Ethylcellulose is practically insoluble in glycerine, propylene glycol and 
     water.
2.   EC  that  contains  less  than  46.5%  of  ethoxyl  groups  is  freely  soluble  in 
      chloroform, ethanol, ethyl acetate, methanol and toluene.
Melting point: Glass transition temperature – 129-133ºC.
Stability and Storage Conditions: Ethyl cellulose is  stable, slightly hygroscopic
materials.  It is subjected to oxidative degradation in the presence of sunlight or  UV
light at  elevated tempera tures . It  should  not  be  stored  at  temperature exceeding
32ºC (90ºF).
Safety: Ethyl cellulose is widely used in oral and topical pharmaceutical formulations.  It
is not metabolized following oral consumption and is therefore a non-calorific substance.
Ethyl cellulose is generally regarded as non-toxic, non-  allergic and non-irritating
material.
Handling  Precautions:  It  is  important  to  prevent  fine  dust  clouds  of  ethyl cellulose
from reaching potentially explosive levels in  air.  Ethyl cellulose is  combustible.  EC
powder may be an irritant to the eyes and eye protection should be worn.
2. Colloidal Silicon Dioxide
Synonyms:
Aerosil,  Cab-O-Sil,  colloidal  silica,  light  anhydrous  silicic  acid,  silicic  anhydride,
Silicon dioxide fumed.
Description:
Colloidal silicon dioxide is submicroscopic fumed silica with a particle size of about
15nm.It  is  a  light,  loose,  bluish-white-colored,  odorless,  tasteless,  non-gritty  amorphous
powder.
Chemical Name: Silica
Empirical Formula: SiO2
Molecular Weight: 60.08
Functional Category: Adsorbent, anti caking agent, glidant, tablet Disintegrant, viscosity-
increasing agent.
Application in Pharmaceutical Formulation:
 Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food
products.
 Colloidal silicon dioxide is also used to stabilize emulsions and as a thyrotrophic
thickening and suspending agent in gels and semisolid preparations.
 Colloidal silicon dioxide is also used as a tablet disintegrant and as an adsorbent,
dispersing agent for liquids in powders.
Stability and Storage Condition:
 Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water
without liquefying.
 Colloidal silicon dioxide powder should be stored in well-closed container.
Incompatibilities:
Incompatible with diethylstilboestrol preparations.
Safety:  Colloidal  silicon  dioxide  is  widely  used  in  oral  and  topical  pharmaceutical
products and is generally regarded as an essentially non-toxic and non-irritant excipient56.
MATERIALS AND METHODS
EXPERIMENTAL SECTION
       Preformulation studies
Preformulation testing is the first step in the rational development of dosage forms of
the drug.  It  can  be  defined  as  investigation of  physical  and  chemical  properties  of  drug
substance,  alone  and  when  combined  with  excipients.   The  overall  objective  of
preformulation testing is to generate information useful to the formulator in developing stable
and bioavailable dosage forms, which can be mass-produced.
A thorough  understanding  of  physicochemical  properties  may  ultimately  provide  a
rational  for formulation design or  support  the need for  molecular  modification or  merely
confirm that there are no significant barriers to the compounds development.  The goals of
the program therefore are 
• To establish the necessary physicochemical characteristic of a new drug substance.
• To establish its compatibility with different excipients.
Solubility analysis
Preformulation solubility analysis  was done to  select  a  suitable solvent  system to
dissolve the drug as well as various excipients used for formulation and also to test drugs
solubility in the dissolution medium, which is to be used.
Preparation of calibration curve for Clarithromycin
Preparation of Potassium dihydrogen ortho phosphate solution
0.476 g of potassium dihydrogen ortho phosphate was dissolved in water and made up
to 100 ml with water and added one drop of orthophosphoric acid to make pH 4.4.
Procedure for construction of calibration curve of Clarithromycin
Clarithromycin,  25  mg  was  dissolved  in  50  ml  of  Potassium  dihydrogen  ortho
phosphate   solution pH 4.4 (500µg/ml). From it, 5 ml was withdrawn and volume was made
up to 50 ml with Potassium dihydrogen ortho phosphate buffer pH 4.4   (stock solution
50µg/ml).  A series of dilutions were made from the above stock solution to get the solutions
of concentration ranging from 20-100 µg/ml. From this solution 1 ml solution was taken and
add 2 ml Folin reagent (1 ml diluted with 2 ml water) & add 2 ml 20 % sodium caronate and
add potassium dihydrogen ortho phosphate buffer to make 10 ml, absorbance of solutions
were measured visible spectrophotometrically at 760 nm. 
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Compatibility studies of Clarithromycin and polymers
FTIR spectra help to confirm the identity of the drug and to detect to the interaction of
the drug with the carriers. 
 Infrared Spectroscopy 
The  IR  absorption  spectra  of  Clarithromycin,  Ethyl  cellulose,  Colloidal  silicon
dioxide  alone  and  in  combination  were  determined  by  Fourier  Transform  Infrared
spectrophotometer using KBr dispersion method.  The obtained spectra were analysed for
functional group of the drug and polymer.
Formulation of Floating microspheres of Clarithromycin
All the formulations were prepared according to the formula given in Table 6. The
microparticles were prepared by using ethyl cellulose as matrix material and colloidal silicon
dioxide (Aerosil) was used as porous material. In the first six formulations Clarithromycin
and Ethyl cellulose were dissolved in dichloromethane (F1-F6) and next six  formulations
(F7-F12)   Clarithromycin  and  Ethyl  cellulose  were  dissolved  in  ethanol,  then  aerosol
(colloidal silicon dioxide)  was suspended uniformly in drug polymer solution. The solution
was stirred  with a  propeller-type  agitator  at  room temperature  for  1  hr  at  150 rpm. The
formed floating microparticles were dried at room temperature in desiccators.
               
FORMULATION DESIGN
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Table No.6: Composition of Clarithromycin floating microspheres.
Materails
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
DRUG
(CLARITHROMYCIN)(mg)
500 500 500 500 500 500 500 500 500
50
0
50
0
50
0
ETHYL CELLULOSE (mg)
_ 50 100 200 300 400 _ 50 100
20
0
30
0
40
0
AEROSIL (mg)
50 50 50 50 50 50 50 50 50 50 50 50
DICHLOROMETHANE(ml)
10 10 10 10 10 10 _ _ _ _ _ _
ETHANOL (ml)
_ _ _ _ _ _ 10 10 10 10 10 10
EVALUATION OF FLOATING MICROPARTICLES
Scanning electron microscopy
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Scanning electron microscopic studies were was carried out on formulation F2. Dry
microparticles were placed on an electron microscope brass stub a coated with gold in an ion
sputter. Then picture of microparticle were taken by random scanning of the stub. The SEM
analysis of the microspheres was carried out by using Tescan analytical scanning electron
microscope. The microspheres were viewed at an accelerating voltage of 20KV.
Micromeritic properties
The microparticles were characterized by their micromeritic properties such as particle
size, bulk density, tapped density, compressibility index, Hausners ratio and angle of repose44.
a. Weight distribution of microparticles
Size distribution of the microparticles was determined by using standard test sieves.
Microparticles retained on the sieves were collected and weighed and the distribution was
analysed based on the weight fraction on each sieve57.
b. Bulk density
In  this  method  floating microparticles  are  transferred  to  a  measuring  cylinder  and  is
tapped  manually  till  a  constant  volume  is  obtained.  This  volume is  bulk  volume  and  it
includes true volume of the powder and the void space among the microparticles 58
      Bulk density = Mass of microparticle/ Bulk volume
c. Tapped density
 In this method floating microparticles were transferred to a measuring cylinder & 
tapped for 100 times. After tapping volume of microparticles was visually examined. The 
ratio of mass of microspheres to volume of microspheres after tapping gives tapped density 
floating microspheres44, 58.
Tapped density = Mass of microparticles/ Volume of microparticles after tapping
c. Carr’s Compressibility index
       Carr’s Compressibility index was determined by using the formula,
             Carr’s Compressibility index = 1-V/V0
             Here V and V0 are the volumes of the sample after and before the standard tapping,    
respectively57.
    Table No.7: Relalationship between Carr’s compressibility index and flowability
Carr’s Compressibility index Flowability
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5-15 Excellent
12-16 Good
18-21 Fair to passable
23-35 Poor
33-38 Very poor
>40 Extremely poor
d. Hausners ratio
            Hausners ratio of microparticle was determined by comparing tapped density to bulk 
density using the equation58
Hausners ratio = Tapped density / Bulk density
e. Angle of repose
     Angle of repose (θ) of the micro particle, which measures the resistance to particle flow,
was determined by a fixed funnel method. The height of the funnel was adjusted in such a
way that  the  tip  of  the  funnel  just  touches  the  heap  of  the  blends.  Accurately  weighed
microparticles were allowed to pass through the funnel freely onto the surface. The height
and radius of the powder cone was measured and angle of repose was calculated using the
following equation44.
θ = tan-1 h/r
Where,
θ = Angle of repose
h= Height of granules above the flat surface
r= Radius of the circle formed by the granule heap
              Table No.8: Relationship between angle of repose and flowability
Angle of Repose Flowability
<20 Excellent
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20-30                            Good
30-34 Passable
>40 Very poor
Yield of floating microspheres
The  prepared  floating  microparticles  were  collected  and  weighed.  The  measured
weight was divided by total amount of all non volatile components which were used for the
preparation of microparticles.
% yield = (Actual weight of product/ Total weight of excipient and drug) × 100
In-vitro Buoyancy
              Floating microparticles (equivalent to 500 mg) were dispersed in 900 ml of 0.1N
hydrochloric  acid  solution  containing  tween  80  (0.01w/v  %)  /tween  20  (0.02w/v  %)  to
simulate gastric fluid at 370C. The mixture was stirred with a paddle at 100 rpm and after 12
hr;  the  layer  of  buoyant  microparticle  (Wf)  was  pipette  and  separated  by  filtration.
Simultaneously sinking microparticle (Ws) was also separated. Both microparticle types were
dried at 400C overnight. Each weight was measured and buoyancy was determined by the
weight ratio of the floating microparticle to the sum of floating and sinking microparticle.
Buoyancy (%) = [Wf /(Wf+Ws)]×100
Where Wf and Ws are the weights of the floating and settled microparticle respectively.
Incorporation efficiency
Floating microparticles  were dissolved in a minimum amount of methanol and drug was
extracted into 0.1 N hydrochloric acid by evaporating methanol. The solution was filtered
through  whatman  filter  paper,  diluted  suitably  and  analyzed  for  drug  content  visible
spectophotometrically at 760 nm using 0.1N hydrochloric acid as blank.
Crushing strength
          Sample Preparation:
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 Strips  of  adhesive  tape correspond to  the  P/25 probe.  The strips  of  tape  (adhesive side
upwards) onto a clean surface and gently pour the sample over the tape. After application of
the sample, lift the tape and gently shake to ensure an even covering of the surface. Tip the
excess sample off.
Test Set-Up:
Before testing, the probe must be calibrated against the machine base and returned to
a set distance (It is important to start all tests from the same distance above the machine base
for comparison when a button trigger is specified). The prepared tapes are placed under the
clean probe, after ensuring the surface under the tape is completely flat and clean of debris,
which would produce erroneous results. The compression test is commenced and repeated on
other regions of the tape.
In-vitro Drug release
Floating microparticle equivalent  to 500 mg of drug was carried out using paddle
method at 50 rpm, up to 3 hrs. 2ml of sample were withdrawn at different time intervals and
replaced with 0.1N HCl, and make up to 10 ml with buffer. From this solution 1 ml solution
was taken and add 2 ml Folin reagent (1 ml diluted with 2 ml water) & add 2 ml 20 % sodium
carbonate and add 0.1N HCl to make 10 ml, the amount of drug release was analyzed at 760
nm using Systronics  visible spectrophotometer.
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RESULTS
In this present study Clarithromycin microparticles were prepared by using by using
ethyl cellulose as matrix material and colloidal silicon dioxide (Aerosil) as porous material.
The solvents, dichloromethane and ethanol were used for the preparation of microparticles. 
PREFORMULATION STUDIES
     a) Standard calibration curve of Clarithromycin
A calibration  curve  (fig  9)  was  plotted  by  taking  the  different  concentration  of
Clarithromycin i.e. from 20 to 100 µg/ml on X-axis and obtained absorbance at 760nm on Y-
axis. The data are given in Table. 9 and the figure is given below
Absorbance values of Clarithromycin in Potassium dihydrogen ortho phosphate buffer 
Ph 4.4 at 760nm
TABLE:9
S.No Concentration
µg/ml
Absorbance 
at 760 nm
1 0 0
2 20 0.016
3 40 0.048
4 60 0.072
5 80 0.108
6 100 0.124
Fig : 9  : Standard calibration curve for Clarithromycin
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  b) Infrared Spectroscopy study
                  IR spectral studies for the identification of pure Clarithromycin, Ethyl cellulose,
Aerosil  and  mixture  of  Drug  & Aerosil  and  Drug,  Ethyl  cellulose  &  Aerosil  shows  no
interaction between them, which indicate that the drug is compatible with Ethyl cellulose and
colloidal silicon dioxide and hence safe and stable formulations can be made.
             The IR Spectra are given in fig 10-14; Table.10 shows the wave number for group
assigned in the infrared spectra of pure drug Clarithromycin.
Table No: 10
                                IR spectral data of pure Clarithromycin
S.No Frequency (cm-1) Group Assigned
1 3470.94 O-H Stretching vibration
2 2976.29 C-H Stretching vibration
3 2940.95 C-H Stretching vibration
4 1732.75 C-O Stretching vibration
5 1692.23 C=O Stretching vibration
6 1051.73 O-H Stretching vibration
7 1010.48 C-O Stretching vibration
8 1251.69 C-N Stretching vibration
9 1282.51 C-N Stretching vibration
10 1109.50 C-O-C stretching vibration
11 839 C-H deformation
Infrared  spectra  for  pure Ethyl  cellulose  polymer  was identified by using Fourier
transform infrared spectrometer by using KBr disk method.
The following Table 11 shows the wave number for group assigned in the infrared
spectra of pure Ethyl cellulose 
Table no: 11
                       IR spectra data of pure Ethyl cellulose
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S.No Frequency (cm-1) Group Assigned
1 3481.81 O-H Stretching
2 2977.45 C-H Stretching
3 2875.55 C-H Stretching
4 1312.60 C-O Stretching
5 1379.10   O-H deformation
6 881.09 C-H deformation
7 1111.89 C-O-C stretching vibration
Infrared spectra for pure Aerosil was identified by using Fourier transform infrared
spectrometer by using KBr disk method.
The following table.12 shows the wave number for group assigned in the infrared
spectra of pure Ethyl cellulose
Table no: 12
                                               IR spectra data of pure Aerosil
S.No Frequency (cm-1) Group Assigned
1 3427.39 O-H Stretching
2 2928.16 C-H Stretching
3 1720.31 C-O Stretching
4 807.47 C-H deforming
5 1102.53 O-H Stretching
FTIR spectra data for mixture contain Clarithromycin & Aerosil were identified the
wave number for group assigned in the infrared spectra shown in following table.13
Table No :13
             IR spectral data of physical mixture of Clarithromycin & Aerosil
S.No Frequency (cm-1) Group Assigned
1 3467.06 O-H Stretching
2 2976.74 C-H Stretching
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3 1734.23 C-O Stretching
4 1656.02 C=O Stretching
5 1103.50 C-O-C Strtching
6 806.13 C-H deformation
7 1580.95 C=C Stretching
8 1459.51 C-H deformation
FTIR spectra data for mixture contain Clarithromycin, Aerosil & Ethyl cellulose were
identified the wave number for group assigned in the infrared spectra shown in following
table.14
Table No :14
             IR spectral data of physical mixture of Clarithromycin, Aerosil & Ethyl cellulose
S.No Frequency (cm-1) Group Assigned
1 3467.26 O-H Stretching
2 2977.21 C-H Stretching
3 1734.10 C-O Stretching
4 1690.50 C=O Stretching
5 1377.73 C-N Stretching
6 1104.71 C-O-C Stretching
7 806.78 C-H deformation
                                    Fig : 10  : IR Spectra of Clarithromycin
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                                              Fig : 11  : IR Spectra of Ethyl cellulose
                    Fig : 12  : IR Spectra of Colloidal silicon dioxide (Aerosil)
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                       Fig : 13  : IR Spectra of mixture of Drug and Aerosil
             Fig : 14  : IR Spectra of mixture of Drug, Aerosil & Ethyl cellulose
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EVALUATION OF CLARITHROMYCIN MICROPARTICLE
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Scanning electron microscopy (SEM) 
Morphology of microparticle was examined by scanning electron microscopy. The
view of the microparticle showed an irregular structure with a moderately smooth surface
morphology. Scanning electron microphotographs of floating microparticle of Clarithromycin
are shown in figure 15
Fig No 15: Scanning electron microphotograph of  floating microparticles of 
Clarithromycin.
 
(a)                                                                                     (b)
      
                                       (c)                                                                       (d)                                             
 Micromeritic properties
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        The microparticles were characterized by their micromeritic properties such as particle
size, bulk density, tapped density, compressibility index and angle of repose. The particle size
was measured by sieve analysis. The results are given in Table (15, 16) & Fig (16, 17).  The
flow properties are expressed in terms of Carr’s index. The value of bulk density, tapped
density, compressibility index and angle of repose are given in Table (17, 18).
Table 15: Mean particle size of of floating microparticles of Clarithromycin using 
Dichloromethane as solvent 
Formulation code             particle size (mean±sd) n=3
                               (mcg)
F1 266.07±1.25
F2 291.01±2.36
F3 302.77±2.68
F4 308.86±1.69
F5 312.71±3.25
F6 317.84±2.95
Fig No.16: Comparison of average particle size of floating microparticle of 
Clarithromycin using Dichloromethane as solvent
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Table 16: Mean particle size of of floating microparticle of Clarithromycin using 
Ethanol as solvent  
Formulation code
particle size (mean±sd) n=3
F7 270.49±2.32
F8 302.52±1.65
F9 313.07±3.54
F10 317.82±3.25
F11 321.26±1.25
F12 325.27±2.78
Fig No.17: Comparison of average particle size of floating microparticle of 
Clarithromycin using Ethanol as solvent 
Table 17: Micromeritic property of floating microparticles of Clarithromycin using 
Dichloromethane as solvent
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Formulation
Code
Bulk
Density
(gm/cm3)
Tapped
Density
(gm/cm3)
Carrs
Index
Hausners
ratio
Angle of
Repose
F1 0.442 0.486 9.05 1.10 290.32’
F2 0.441 0.539 18.18 1.22 370.40’
F3 0.483 0.590 18.14 1.22 360.42’
F4 0.510 0.611 16.53 1.20 350.31’
F5 0.552 0.651 15.21 1.18 350.24’
F6 0.610 0.714 14.57 1.17 340.10’
Table 18: Micromeritic property of floating microparticle of Clarithromycin using 
Ethanol as solvent
Formulation
Code
Bulk
Density
(gm/cm3)
Tapped
Density
(gm/cm3)
Carrs
Index
Hausners
ratio
Angle of
Repose
F7 0.412 0.450 8.4 1.09 270.15’
F8 0.333 0.408 18.38 1.23 340.20’
F9 0.374 0.452 17.26 1.21 330.15’
F10 0.404 0.482 16.18 1.19 330.01’
F11 0.451 0.538 16.17 1.19 320.46’
F12 0.494 0.572 13.64 1.16 310.22’
Optical microscopy
Determination of average particle size of Clarithromycin floating microparticles was 
carried out by Optical microscopy in which stage micrometer was employed. Phase contrast 
microscope was used here. The results are given in the fig no (18, 19).  
 Fig No.18 Microscopic image showing microparticles of Clarithromycin formulation (a)
F1 (b) F2 (c) F3 (d)F4 (e)F5 (f)F6
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                   F1                                                              F2                                                               F3
                     
                         F4                                                  F5                                                          F6                                   
Fig No.19 Microscopic image showing microparticles of Clarithromycin formulation (a) 
F7 (b) F8 (c) F9 (d)F10  (e)F11 (f)F12.   
             
                        F7                                                 F8                                                       F9
                                 
                  
                  F10                                                              F11                                                        F12
Percent yield of microparticles
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The  yields  of  preparation  of  Clarithromycin  microparticles  are  high  for  all
microparticles obtained which are about 90%. It shows that the recovery of the material is
good which is significant from the economical view. The results are given in Table (19, 20) &
Fig (20, 21). 
Table 19: Percentage yield of of floating microparticle of Clarithromycin using 
Dichloromethane as solvent  
Formulation code Percentage yield
(%)
F1 92.73
F2 93.45
F3 94.36
F4 96.00
F5 96.73
F6 97.82
Figure 20:Comparison of  Percentage yield of of floating microparticle of 
Clarithromycin using Dichloromethane as solvent  
Table :20 Percentage yield of of floating microparticle of Clarithromycin using Ethanol 
as solvent  
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Formulation code
Percentage yield
(%)
F7 90.91
F8 92.55
F9 93.64
F10 94.91
F11 96.36
F12 97.27
Figure No.21:Comparison of  Percentage yield of of floating microparticle of 
Clarithromycin using Ethanol as solvent  
In-vitro Buoyancy
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The  buoyancy  test  was  carried  out  to  investigate  the  floatability  of  prepared
microparticles.  The results  showed a tendency that  the larger the particle size,  the longer
floating time. The results are given in Table (21, 22) & Fig No (22-27). 
Table 21 : Invitro Buoyancy of of floating microparticle of Clarithromycin using 
Dichloromethane as solvent  
Formulation code Invitro Buoyancy
(%)
F1 70.34
F2 78.45
F3 80.81
F4 82.37
F5 88.31
F6 92.12
Figure 22:Comparison of  Invitro Buoyancy of of floating microparticle of 
Clarithromycin using Dichloromethane as solvent  
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Table 22 : Invitro Buoyancy of of floating microparticle of Clarithromycin using Ethanol
as solvent  
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Formulation code
Invitro Buoyancy
(%)
F7 69.86
F8 76.31
F9 79.43
F10 80.97
F11 86.48
F12 91.87
Figure No 23 :Comparison of  Invitro Buoyancy of of floating microparticle of 
Clarithromycin using Ethanol  as solvent  
Fig No.24 : In-vitro buoyancy of floating microparticles of Clarithromycin formulation 
(a)F1,(b)F2,(c)F3.
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Fig No.25 : In-vitro buoyancy of floating microparticles of Clarithromycin formulation (a)F4,
(b)F5,(c)F6
Fig No.26 : In-vitro buoyancy of floating microparticles of Clarithromycin formulation 
(a)F7,(b)F8,(c)F9
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Fig No.27 : In-vitro buoyancy of floating microparticles of Clarithromycin formulation 
(a)F10,(b)F11,(c)F12
 Incorporation efficiency
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   The incorporation efficiency was found to be good in all the prepared formulation.
Results  demonstrated  that  increase  in  concentration  of  ethyl  cellulose,  increased  the
entrapment of the drug. The results are given in the Table (23, 24) & Fig No (28, 29).
Table 23 : Incorporation Efficiency of of floating microparticle of Clarithromycin using 
Dichloromethane as solvent  
Formulation code
Incorporation  Efficiency
F1 91.22
F2 92.24
F3 93.98
F4 95.42
F5 95.99
F6 96.87
Figure No.28:Comparison of Incorporation Efficiency  of of floating microparticle of 
Clarithromycin using Dichloromethane as solvent  
Table 24: Incorporation Efficiency of of floating microparticle of Clarithromycin using 
Ethanol as solvent  
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Formulation code Incorporation Efficiency
F7 89.98
F8 91.09
F9 92.45
F10 93.76
F11 95.04
F12 96.54
Figure No.29:Comparison of Incorporation Efficiency  of of floating microparticle of 
Clarithromycin using Ethanol as solvent  
Crushing strength
Crushing strength of  Clarithromycin  from floating microparticles  were performed
using T.A.X.T plus Texture Analyser. Results demonstrated that increase in concentration of
Ultra College of Pharmacy, Madurai PAGE 70 
RESULTS
ethyl cellulose, increased crushing strength of the microparticle. The results are given in the
Table. 25 & Fig (30, 31). 
Table no : 25 Crushing strength of F1-F12
S.No Formulation code
Crushing strength
N
1 F1 50.579
2 F2 54.921
3 F3 44.549
4 F4 48.807
5 F5 74.354
6 F6 101.987
7 F7 7.947
8 F8 5.814
9 F9 11.758
10 F10 49.255
11 F11 79.206
12 F12 109.069
Figure No.30: The crushing strength of F1-F6.
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Figure No.31: The crushing strength of F7-F12.
In-vitro drug release studies
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The  dissolution  study  was  carried  out  for  3  hours  for  all  formulation.  The  drug
released study was carried out by using USP type 2 dissolution test apparatus. Microparticles
were studied at Potassium dihydrogen ortho phosphate   buffer Ph 4.4. The Clarithromycin
microparticles were analysed for in-vivo drug release estimation the result given in the table
no:(26-37). Among all formulations, F2 was found to be the best formulation as it release
Clarithromycin 98.07% in a sustained manner with constant fashion over extended period of
time. The Clarithromycin microparticles were analysed for  in-vitro  drug release estimation
the result given in the table no: (26-37) & fig no (32-45)
Table No:26
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                         IN-VITRO DRUG RELEASE DATA FOR F1
S.No Time in min Cumulative % drug release
1 0 0
2 30 5.25
3 60 13.5
4 90 24
5 120 36
6 180 47.25
     Fig No;32 IN-VITRO DRUG RELEASE GRAPH OF F1
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 Table no :27
IN-VITRO DRUG RELEASE DATA FOR F2
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S.No Time in min Cumulative % drug release
1 0 0
2 30 24.08
3 60 40.89
4 90 60.46
5 120 80.84
6 180 98.07
     No:33 IN-VITRO DRUG RELEASE GRAPH OF F2
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Table No:28
                                   IN-VITRO DRUG RELEASE DATA FOR F3
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S.No Time in min Cumulative % drug release
1 0 0
2 30 19.08
3 60 31.33
4 90 39.45
5 120 66.89
6 180 88.01
No:34 IN-VITRO DRUG RELEASE GRAPH OF F3
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Table No.29
                                                 IN-VITRO DRUG RELEASE DATA FOR F4
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S.No Time in min Cumulative % drug release
1 0 0
2 30 16.50
3 60 28.50
4 90 30.75
5 120 60
6 180 82.50
Fig No:35 IN-VITRO DRUG RELEASE GRAPH OF F4
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Table No:30
                              IN-VITRO DRUG RELEASE DATA FOR F5
S.No Time in min Cumulative % drug release
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1 0 0
2 30 11.25
3 60 19.50
4 90 28.50
5 120 42.75
6 180 67.5
Fig No:36  IN-VITRO DRUG RELEASE GRAPH OF F5
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Table No:31
                          IN-VITRO DRUG RELEASE DATA FOR F6
S.No Time in min Cumulative % drug release
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1 0 0
2 30 5.25
3 60 8.26
4 90 29.25
5 120 47.25
6 180 54.75
Fig No:37  IN-VITRO DRUG RELEASE GRAPH  OF F6
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Table No:32
                           IN-VITRO DRUG RELEASE DATA FOR F7
S.No Time in min Cumulative % drug release
1 0 0
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2 30 12.27
3 60 26.28
4 90 38.22
5 120 48.07
6 180 64.08
Fig: 38 IN-VITRO DRUG RELEASE GRAPH OF F7
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Table No:33
IN-VITRO DRUG RELEASE DATA FOR F8
S.No Time in min Cumulative % drug release
1 0 0
2 30 20.86
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3 60 38.86
4 90 52.9
5 120 76.48
6 180 94.02
Fig:39  IN-VITRO DRUG RELEASE GRAPH OF F8
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Table No:34
                                     IN-VITRO DRUG RELEASE DATA FOR F9
S.No Time in min Cumulative % drug release
1 0 0
2 30 18.05
3 60 34.07
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4 90 46.02
5 120 70.82
6 180 84.17
Fig :40 IN-VITRO DRUG RELEASE GRAPH OF F9
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Table :35
                           IN-VITRO DRUG RELEASE DATA FOR F10
S.No Time in min Cumulative % drug release
1 0 0
2 30 15.83
3 60 31.29
4 90 42.06
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5 120 66.65
6 180 78.08
Fig: 41 IN-VITRO DRUG RELEASE GRAPH OF F10
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Table No:36
IN-VITRO DRUG RELEASE DATA FOR F11
S.No Time in min Cumulative % drug release
1 0 0
2 30 13.20
3 60 27.02
4 90 38.69
5 120 56.42
6 180 64.08
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Fig: 42 IN-VITRO DRUG RELEASE GRAPH OF F11
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Table No: 37
IN-VITRO DRUG RELEASE DATA FOR F12
S.No Time in min Cumulative % drug release
1 0 0
2 30 10.25
3 60 22.47
4 90 34.42
5 120 40.86
6 180 48.65
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Fig:43 IN-VITRO DRUG RELEASE GRAPH OF F12
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Fig No: 44  Invitro drug release comparison data for F1, F2, F3, F4, F5, F6.
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Fig No: 45 Invitro drug release comparison data for F7, F8, F9, F10, F11, F12.
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Study of drug release kinetics
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In order to find out the drug release and mechanism, the invitro release data subjected
to the different mode of graphical treatment.
1. The percentage cumulative drug release Vs Time.
2. The cumulative percent drug remaining Vs Time.
The release mechanism of Clarithromycin from various formulations was determined
by comparing their respective correlation coefficient13. The results are shown in Table.38 &
Fig 46. 
Table: 38
Kinetic analysis of release data for Hixson Crowell model
Batch No
Regression coefficient (R2)
F1 0.984
F2 0.971
F3 0.981
F4 0.968
F5 0.992
F6 0.925
F7 0.986
F8 0.978
F9 0.971
F10 0.968
F11 0.958
F12 0.946
Fig:46  Hixson Crowell model for Batch-F5
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DISCUSSION
Floating drug delivery systems remain buoyant in the stomach as they have a bulk
density less than gastric fluids and thus prolonging the stay of the dosage form in stomach.
While the system is floating on the gastric contents, the drug is released slowly at the desired
rate from the system. After release of drug, the residual system is emptied from stomach. This
results in an increased gastric residence time and a better control of the fluctuation in plasma
drug concentration. Single unit formulations (floating tablet) are associated with problems
such as sticking together or being obstructed in the gastrointestinal tract, which may have a
potential danger of producing irritation. On the other hand a floating system made of multiple
unit forms (floating microparticles) has relative merits compared to a single unit preparation.
Floating microparticles provide a constant and prolonged therapeutic effect which will reduce
dosing frequency27.
Floating multiparticulate dosage form have been prepared by solvent diffusion and
solvent evaporation method to create an hollow inert  core 26,  27.  Porous calcium pectinate
beads with bulk density less  than 1 were prepared by Badve SS39.  Alternatevely floating
microparticles based on low density foam powder were prepared with polypropylene foam
powder, matrix forming polymer and the drug (Verapamil HCL)28. Instead of foam powder
highly porous carrier material like calcium silicate was used along with Eudragit S to deliver
Repaglinide over an extend period of time. In  the present study, colloidal silicon dioxide
(Aerosil)  was  used  as  the  porous  material.  Colloidal  silicon  dioxide  is  hygroscopic  but
adsorbs large quantities of water without liquefying29.
The aim of present study was to develop floating microparticles of Clarithromycin by
using ethyl cellulose as matrix material and colloidal silicon dioxide (Aerosil) as the porous
material.  Calibration  curve  for  the  estimation  of  Clarithromycin  was  constructed  by  a
colorimetric method which obeyed Beer’s Lambert law in the range of 20-100 mcg/ml.
Infrared spectroscopy
Drug- excipient  compatibility was assessed by FTIR spectroscopy to find out any
chemical  interaction  between  Clarithromycin  and  excipients  used.  The  FTIR  spectra  of
Clarithromycin,  polymer  (ethyl  cellulose)  and  selected  formulations  as  shown  in  the
figure(10-14) revealed the same transmittance pattern for the drug, drug with polymer and
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drug, ethyl cellulose and colloidal silicon dioxide. Hence further formulation studies were
extended.
Preparation of microparticles
Totally  12  formulations  are  prepared.  Clarithromycin  floating  microparticle
formulation  F1  to  F6  containing  ethyl  cellulose  using  dichloromethane  as  solvent  and
formulation F7 to F12 containing ethyl cellulose using ethanol as solvent. 
Scanning electron microscopy 
Morphology of microparticle was examined by scanning electron microscopy. The
view  of  the  microspheres  showed  an  irregular  shape  with  a  moderately  smooth  surface
morphology.
Some of  the  microparticle  showed a  dented  surface  structure  (fig  15),.  The  outer
surface of the microparticle was dense and pores could be observed. The microparticle also
showed some porous structure. It  may be caused by the evaporation of solvent entrapped
within the microspheres  after forming a dense skin layer,  but  they showed good floating
ability on the surface of the medium, indicating intact surface. 
Micromeritic properties
The mean particle size of the floating microparticle formulation F1 to F6 containing
ethyl cellulose using dichloromethane as solvent and formulation F7 to F12 containing ethyl
cellulose  using ethanol as solvent was in range of  266.07 to 317.84 µm and 270.49-325.27
µm respectively (as shown in table 15, 16). The mean particle size of the microparticle was
found to increase with increasing ethyl cellulose concentration. The viscosity of the medium
increases at a higher ethyl cellulose concentration. Shearing efficiency is also diminished at
higher viscosities. This results in the formation of larger particles with greater ethyl cellulose
concentration.
The bulk density, tapped density of formulation F1 to F6 containing ethyl cellulose
using dichloromethane as solvent and formulation F7 to F12 containing ethyl cellulose using
ethanol  as  solvent  was  in  range  of  0.441  to  0.610  gm/cm3,  0.333  to  0.494  gm/cm3
respectively, 0.486 to 0.0.714 gm/cm3, 0.408 to 0.572 gm/cm3 respectively, (as shown in table
17, 18).
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The carr’s index, Hausners ratio, angle of repose of formulation F1 to F6 containing
ethyl cellulose using dichloromethane as solvent and formulation F7 to F12 containing ethyl
cellulose using ethanol as solvent was in range of   9.05 to 14.57, 8.4 to 13.64  respectively,
1.10 to 1.22, 1.09 to 1.23 respectively, 290.32’ to 370.40’, 270.15’ to 340.20’ respectively (as
shown in table 15, 16).Hausners ratio for all formulation was less than 1.25 indicate good
flow. The flow properties are expressed in terms of carr’s index. The carr’s  index for all
formulation was less than 15. This indicates excellent flow compared to the original drug.
The  improvement  in  flow  properties  and  suggests  that  the  microparticles  can  be  easily
handled during processing. 
Yield of floating microsphere
The percentage yield of floating microparticle formulation F1 to F6 containing ethyl
cellulose  using  dichloromethane  as  solvent  and  formulation  F7  to  F12  containing  ethyl
cellulose using ethanol was in range of 92.73 to 97.82, 90.91 to 97.27  respectively ( as
shown in table 19, 20). To observe the effect of polymer concentration on the percentage
yield of the floating microparticle, formulations were prepared at varying concentration of
ethyl  cellulose.  The yield of the floating microparticle increased with increasing polymer
concentration.  At  low concentration  of  ethyl  cellulose  polymer  solution  aggregated  in  a
fibrous structure,  as  it  solidified prior  to  forming droplets  or  the  transient  droplets  were
broken before solidification was complete due to poor mechanical strength resulting into low
yield.
In-vitro buoyancy
The purpose of preparing floating microparticle is to extend the gastric residence time
of a drug. The buoyancy test was carried out to investigate the floatability of the prepared
microspheres. The microparticles were spread over the surface of a simulated gastric fluid
and  the  fraction  of  microspheres  buoyant  and  settled  down  as  a  function  of  time  was
quantitated. The in-vitro buoyancy of formulation F1 to F6 containing ethyl cellulose  using
dichloromethane  as  solvent  and  formulation  F7  to  F12  containing  ethyl  cellulose  using
ethanol as solvent was range from 70.34 to 92.12 %, 69.86 to 91.87 % respectively ( as
shown in table  21,  22).  Among all  formulation  F6  was found to  possess  highest  invitro
buoyancy 92.12%. The results also showed a tendency that the larger the particle size, the
longer floating time.
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Incorporation efficiency
The  drug  Incorporporation  efficiency  of  formulation  F1  to  F6  containing  ethyl
cellulose  using  dichloromethane  as  solvent  and  formulation  F7  to  F12  containing  ethyl
cellulose  using  ethanol  as  solvent  was  in  range  of  91.22   to  96.87,   89.98   to   96.54
respectively  ( as shown in table 23, 24). Results demonstrated that increase in concentration
of ethyl cellulose, increased the entrapment of the drug. The drug entrapment efficiency was
found to be good in all the formulation.
Crushing strength
The compressive strength or crushing strength of granules has been investigated by
placing  individual  granules  between  platens  and  breaking  them  by  application  of  a
compressive  load.  In  many formulations,  there  is  an  optimum range  of  average  granule
crushing strength for a given granule size. Granule strengths below the lower limit of this
range  may  consolidate  well,  but  tend  to  break  down  during  mixing,  handling  and
precompression, to generate fines which retard uniform die filling59.
            Crushing strength of Clarithromycin from floating microspheres were performed
using T.A.X.T plus Texture Analyser. Crushing strength of formulation F1 to F6 containing
ethyl cellulose using dichloromethane as solvent and formulation F7 to F12 containing ethyl
cellulose using ethanol as solvent was in range of 50.579 to 101.987 N, 5.814 to 109.069 N
respectively  ( as shown in table 21, 22 ). Results demonstrated that increase in concentration
of ethyl cellulose, increased crushing strength of the microparticle (fig 30, 31).
In-vitro drug release
In-vitro  drug  release  studies  of  Clarithromycin  from  floating  microparticle  were
performed in 0.1N HCl for 3 hr using USP type 2 dissolution test apparatus. It was found that
invitro drug release of formulation F1 to F6 containing ethyl cellulose using dichloromethane
as solvent and formulation F7 to F12 containing ethyl cellulose using ethanol as solvent as
follows
F1, F3, F4, F5, F6 show percentage drug release 47.25 to 97.79 % at end of 3 hour.
Formulation F2 show percent drug release 98.07 % at end of 3 hr. While F7, F9, F10, F11,
F12 show percentage drug release 48.65 to 84.17 % at end of 3 hour  ( as shown in table 26-
37)  and  formulation  F8  show percent  drug  release  94.02  % at  end  of  3  hr.  Among all
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formulations, F2 was found to be the best formulation as it release Clarithromycin 98.07 % in
a sustained manner with constant fashion over extended period of time.
It was observed as the concentration of ethyl cellulose was increased percent release
of  Clarithromycin  decreases.  The  increase  in  ethyl  cellulose  concentration  leads  to  the
increased density of  polymer matrix  into  the  microparticle  which  results  in  an  increased
diffusional  pathlength.  This  may decrease  the  overall  drug  release  from polymer  matrix.
Furthermore  smaller  microparticles  are  formed  at  lower  polymer  concentration  and  have
larger surface area exposed to dissolution medium.
Drug release kinetics
The release mechanism of Clarithromycin from various formulations was determined
by comparing their  respective  correlation coefficient.  It  shows  that  the  results  pattern  of
Clarithromycin microparticle corresponded best Hixson Crowell model, which shows a linear
relationship between the percent drug remaining to be released Vs Time ( as shown in fig 46).
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SUMMARY AND CONCLUSIONS
Floating microparticles have a bulk density less than gastric fluids and thus it remains
buoyant in the stomach without affecting gastric emptying rate for a prolonged period of
time. While the system is floating on the gastric contents, the drug is released slowly at the
desired rate from the system. Also floating microparticle provides a constant and prolonged
therapeutic effect which will reduce dosing frequency.
In  the  present  study,  floating microparticle  of  Clarithromycin  was  prepared  using
polymer like ethyl cellulose by using ethyl cellulose as matrix materials and colloidal silicon
dioxide (Aerosil) was used as the porous materials.
The objective of the study is presented in chapter 3. Initially, an extensive literature
survey was done for the collection of theoretical and technical data. The review of literature,
drug  profile  and  excipient  profiles  are  presented  in  chapter  4.  This  was  followed  by
procurement and characterization of raw materials used in the study.
The  surface  morphology of  the  prepared  floating  microparticle  was  studied  using
scanning electron  microscopy.  The prepared  floating microparticles  also  characterized  by
FTIR  spectroscopy  to  find  out  any  chemical  interaction  between  Clarithromycin  and
polymers  used.  The  prepared  floating  microparticles  were  evaluated  for  particle  size,
percentage yield,  drug incorporation efficiency, micromeritic properties (like bulk density,
tapped density, hausners ratio, angle of repose, compressibility index), in-vitro buoyancy, in-
vitro drug release study, crushing strength and as described in chapter 5. The results indicated
that  the  significant  effect  was  observed  of  increased  polymer  concentration,  on  said
parameters in each case. The details of results are given in chapter 6. The mean particle size
of  the  microparticles  significantly  increased  with  increase  in  polymer  concentration.
Micromeritic study suggested excellent flow properties of prepared microspheres. The invitro
release was in the following order F2>F3>F5>F4>F6>F1 & F8>F9>F10>F11>F7>F12.
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The  results  of  the  present  study  on  “  Development  and  evaluation  of  floating
microparticle of Clarithromycin” reveals following conclusions:
 Floating microparticles of Clarithromycin can be successfully prepared by using ethyl
cellulose  as  matrix  material  and  colloidal  silicon  dioxide  (Aerosil)  as  the  porous
material.
 The  percent  yield  of  all  floating  microparticle  formulation  was  more  than  90%
suggesting that the methods used for drug entrapment was effective. The percent yield
was  significantly  increased  as  the  amount  of  polymer  was  increased  in  each
preparation method.
 The  Incorporation  efficiency  was  good  in  all  the  cases  which   suggested  that
optimized parameters were used in the method of preparations.
 The  in-vitro  buoyancy  was  more  than  70  %  after  4  hours  indicated  satisfactory
performance of proposed formulations. The percent buoyancy increased significantly
as the amount of polymer was increased in each preparation method.
 The  mean  particle  size  of  microparticles  was  in  the  range  of  266.07-325.27µm
depending  upon  the  concentration  of  polymer  used.  The  particle  size  increased
significantly as the amount of polymer increased.
 The flow properties of all the prepared microparticles were good as indicated by low
angle of repose (θ< 400) and low compressibility index . The good flow properties
suggested that the microparticle produced were non-aggregated.
 The  crushing  strength  of  microparticle   was  in  the  range  of  5.814-109.069  N
depending upon the concentration of polymer used. The crushing strength increased
the amount of polymer was increased in each preparation method.
 In-vitro  release  of  floating  microparticle  of  Clarithromycin  was  found  to  be  in
following  order  F2>F3>F5>F4>F6>F1  &  F8>F9>F10>F11>F7>F12.  Among  all
formulations, F2 was found to be the best formulation as it release Clarithromycin
98.07 % in a sustained manner with constant fashion overextended period of time.
Hence,  finally  it  was  concluded  that  the  prepared  Floating  microparticle  of
Clarithromycin may prove to be potential  candidate for safe and effective sustained drug
delivery over an extended period of time.
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